No Data
No Data
Express News | AstraZeneca : Jefferies Raises Target Price to $75.5 From $74
Arcus Biosciences, AstraZeneca Collaborate on Developing Carcinoma Treatment
Express News | Arcus Biosciences Inc - AstraZeneca to Sponsor Study on Casdatifan and Volrustomig Combination
AstraZeneca: Strong Sales and Robust Pipeline Underpin Buy Rating
Eli Lilly and Co (LLY.US) explores new uses for "miracle weight-loss drug" Zepbound, aiming to reduce the incidence of diabetes and other high-risk populations.
eli lilly and co is exploring new uses for its weight loss drug Zepbound to reduce the incidence of diabetes in high-risk populations, even if they are not overweight.
Daiichi Sankyo/AstraZeneca (AZN.US) heavy-duty ADC obtains FDA priority review qualification.
The USA FDA is expected to complete the review in the first quarter of 2025.
No Data
No Data
ひな☆彡 SOXL : You convinced me. I am happy to buy some later.
Growth Investor27 : Long ESPR $1.61 is very cheap.
Growth Investor27 : Long150,000 will hold for 5x upside for 2025 if not aquired.